

In the claims

1-6 (canceled).

7 (currently amended). A pharmaceutical composition comprising a form of a propylene glycol solvate of ~~an active pharmaceutical ingredient (API) selected from olanzapine, cortisone acetate, naproxen, celecoxib trihydrate, celecoxib or salts thereof~~ celecoxib selected from:

- a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:
 - i) any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peaks selected from peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87 or 25.75 degrees; or
 - ii) any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61 or 25.71 degrees;
- b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following peaks: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees;
- c) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern that comprises a peak at 8.21 degrees 2-theta; or
- d) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern that comprises a peak at 8.79 degrees 2-theta.

8-25 (canceled).

26 (currently amended). The composition according to claim 7, wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate and the composition is characterized by a

PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:

- a)—— any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peaks selected from peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87 or 25.75 degrees; ~~or~~
- b)—— ~~any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61 or 25.71 degrees.~~

27 (previously presented). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:

any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following peaks: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees

28 (previously presented). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by a PXRD pattern that comprises a peak at 8.21 degrees 2-theta.

29 (previously presented). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by a PXRD pattern that comprises a peak at 8.79 degrees 2-theta.

30-31 (canceled).

32 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61 or 25.71 degrees.